Insmed Inc (INSM)vsSagimet Biosciences Inc. Series A Common Stock (SGMT)
INSM
Insmed Inc
$148.31
+6.59%
HEALTHCARE · Cap: $29.99B
SGMT
Sagimet Biosciences Inc. Series A Common Stock
$4.62
-0.22%
HEALTHCARE · Cap: $157.06M
Smart Verdict
WallStSmart Research — data-driven comparison
SGMT leads profitability with a 0.0% profit margin vs -2.1%. INSM earns a higher WallStSmart Score of 39/100 (F).
INSM
Hold39
out of 100
Grade: F
SGMT
Avoid26
out of 100
Grade: F
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
No standout strengths identified
Reasonable price relative to book value
Conservative balance sheet, low leverage
Areas to Watch
1.5% revenue growth
0.0% earnings growth
Trading at 43.0x book value
ROE of -2.5% — below average capital efficiency
0.0% revenue growth
0.0% earnings growth
Smaller company, higher risk/reward
0.0% margin — thin
Comparative Analysis Report
WallStSmart ResearchBull Case : INSM
PEG of 1.09 suggests the stock is reasonably priced for its growth.
Bull Case : SGMT
The strongest argument for SGMT centers on Price/Book, Debt/Equity.
Bear Case : INSM
The primary concerns for INSM are Revenue Growth, EPS Growth, Price/Book.
Bear Case : SGMT
The primary concerns for SGMT are Revenue Growth, EPS Growth, Market Cap.
Key Dynamics to Monitor
INSM profiles as a turnaround stock while SGMT is a value play — different risk/reward profiles.
SGMT carries more volatility with a beta of 3.40 — expect wider price swings.
INSM is growing revenue faster at 1.5% — sustainability is the question.
SGMT generates stronger free cash flow (-12M), providing more financial flexibility.
Bottom Line
INSM scores higher overall (39/100 vs 26/100). Both earn "Hold" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Insmed Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Insmed Incorporated, a biopharmaceutical company, develops and markets therapies for patients with rare and serious diseases. The company is headquartered in Bridgewater, New Jersey.
Sagimet Biosciences Inc. Series A Common Stock
HEALTHCARE · BIOTECHNOLOGY · USA
Sagimet Biosciences Inc. (SGMT) is a cutting-edge biotechnology firm specializing in the development of innovative therapies for metabolic diseases, particularly non-alcoholic steatohepatitis (NASH). The company is actively advancing its lead therapeutic candidate through clinical trials, leveraging novel mechanisms aimed at significantly improving patient outcomes. With a seasoned leadership team and a comprehensive intellectual property portfolio, Sagimet is well-positioned to take advantage of the growing demand for effective treatments in the metabolic disease arena, presenting a promising opportunity for institutional investors looking to engage with the evolving biotech market.
Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?